Stock DNTH DIANTHUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-05-22 pm EDT 		5-day change 1st Jan Change
21.77 USD -5.55% Intraday chart for Dianthus Therapeutics, Inc. -14.49% +109.33%
May. 16 HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target MT
May. 10 Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target
MT
Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating
MT
Dianthus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
AQ
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference
AQ
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Lei Meng Announces Not to Stand for Reelection as Director of Dianthus Therapeutics, Inc
CI
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting
AQ
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Wedbush Raises Dianthus Therapeutics' PT to $33 From $24, Says Q4 2023 Results As-Expected, Keeps Outperform Rating
MT
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results
AQ
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)
AQ
Dianthus Therapeutics, Inc. Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis
CI
Stifel Initiates Dianthus Therapeutics With Buy Rating, $44 Price Target
MT
Wedbush Lifts Dianthus Therapeutics' PT to $24 From $23, Updates Estimates Following Private Placement; Keeps Outperform Rating
MT
Dianthus Therapeutics, Inc. announced that it expects to receive $229.997318 million in funding
CI
Jefferies Initiates Dianthus Therapeutics at Buy With $22 Price Target
MT
Dianthus Therapeutics, Inc. Announces Executive Appointments
CI
Wedbush Starts Dianthus Therapeutics With Outperform Rating, $23 Price Target; Sees DNTH103 as Promising Candidate
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DNTH Stock
  4. News Dianthus Therapeutics, Inc.